



## **Dimitrios Zuzoulas**

Greece

As a dedicated gynecologic oncologist with a robust academic and clinical background, I am eager to contribute to the ENYGO Executive Group and propel the advancement of gynecological oncology throughout Europe.

My career reflects a strong commitment to women's cancer care, multidisciplinary collaboration, and research innovation-values that closely align with ESGO's mission. Having completed my ESGO fellowship, I have gained extensive exposure to the highest standards of surgical training, evidence-based care, and international cooperation.

As the acting ENYGO National Representative of Greece, I actively support peer engagement and foster collaboration between young professionals and senior experts.

My current roles as a member of both the ENYGO Clinical Education & Practical Skills Committee and the Communication & Social Media Committee further reflect my dedication to education, training, and the promotion of our community's initiatives.

In addition to academic and professional development, I believe that genuine friendship and camaraderie among peers strengthens our network, inspires open exchange, and makes our community a supportive environment for all.

My efforts are always guided by a spirit of inclusiveness and mutual respect. If elected to the ENYGO Executive Group, I will strive to advance ESGO's vision by facilitating opportunities for learning, excellence, and international cooperation-empowering the next generation of gynecologic oncologists and ultimately improving outcomes for women with cancer.

## **Curriculum vitae**

Recognized for a strong academic background and a commitment to advancing women's cancer care.

Completed medical degree at the School of Medicine of Aristotle University of Thessaloniki (AUTH), followed by a Master's degree in Medical Research Methodology, with research focused on breast cancer in younger women. Achieved PhD with distinction for research addressing the effects of surgical treatment delay on quality of life for endometrial and ovarian cancer patients.

Completed clinical formation through the European Society of Gynaecological Oncology (ESGO) Fellowship, advanced endoscopic surgery training (GESEA MIGS Level 1 & 2), breast surgery specialization as Fellow of the European Board of Surgery (FEBS-BS), comprehensive colposcopy certification (HSCCP) with both theoretical and hands-on modules, and advanced ultrasound training for gynecological and breast applications (IOTA, VITA, CITA, IBUS). Serves as clinical fellow in gynecologic oncology at the 1st Department of Obstetrics & Gynecology, AUTH, Papageorgiou General Hospital, a center certified by ESGO for Advanced Ovarian Cancer Surgery and designated a European Training Center in Gynecological Oncology, engaging fully with the most advanced surgical and educational practices. Manages daily clinical responsibilities alongside academic activities, drawing on extensive training in gynecologic surgery, breast oncology, and translational research.

Acts as National Representative for Greece in ENYGO, contributing actively to the Clinical Education & Practical Skills Committee and the Communication & Social Media Committee. Coordinates educational programs, develops training guidelines, and facilitates cross-border networking for young gynecological oncologists throughout Europe.

Presents research at more than thirty international and national conferences focusing on molecular classification, surgical approaches, quality of life, and fertility-sparing strategies. Contributes to major multicenter trials, including COVIDSurg, CERVANTES, and EUGIENE, and publishes extensively in leading journals, gaining recognition for original research and expert reviews.

Drives improvement in advanced ovarian and endometrial cancer surgery outcomes, fosters surgical innovation, and enhances perioperative care standards. Dedicated to collaboration, mentorship, and the cultivation of collegiality and professional friendship as a foundation for scientific and personal progress. Fully committed to delivering compassionate patient-centered care and contributing actively to research and education in gynecologic oncology.

## PUBLICATIONS

### *Cumulative list of scientific publications & book chapters*

1. Mintziori G, Goulis DG, Gialamas E, Dosopoulos K, **Zouzoulas D**, et al. Association of TSH concentrations and thyroid autoimmunity with IVF outcome in women with TSH concentrations within normal adult range. *Gynecol Obstet Invest.* 2014; 77(2): 84-88.
2. **Zouzoulas D**, Tsolakidis D, Efstratiou I, Pervana S, Pazarli E, Grimbizis G. Correlation between Adenomyosis and Endometrial cancer: 6-year experience of a single center. *Facts Views Vis Obgyn.* 2018;10(3):147-152.
3. Zafrakas M, Papasozomenou P, Eskitzis P, **Zouzoulas D**, Boulogianni G, Zaramboukas T. Cavernous Breast Hemangioma Mimicking an Invasive Lesion on Contrast-Enhanced MRI. *Case Rep Surg.* 2019; 9: 2019:2327892.
4. **Zouzoulas D**, Tsolakidis D, Gitas G, Zafrakas M, Goulis DG, Douganiotis G, Sympilidis G, Grimbizis G. Breast cancer in women younger than 35 years old. *Arch Gynecol Obstet.* 2020; 302(3):721-730.
5. COVIDSurg Collaborative. Delaying surgery for patients with a previous SARS-CoV-2 infection. *Br J Surg.* 2020 Nov;107(12):e601-e602.
6. Gitas G, Proppe L, Baum S, Krugger M, Rody A, Tsolakidis D, **Zouzoulas D**, et al. A Risk Factor Analysis of Complications after Surgery for Vulvar Cancer *Arch Gynecol Obstet.* 2021 Aug;304(2):511-519.
7. Tsolakidis D, **Zouzoulas D**, Pados G. Pregnancy-Related Hysterectomy for Peripartum Hemorrhage: A Literature Narrative Review of the Diagnosis, Management, and Techniques. *Biomed Res Int.* 2021 Jul 6; 2021:9958073.
8. COVIDSurg Collaborative. Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study. *J Clin Oncol.* 2021 Jan 1;39(1):66-78.
9. COVIDSurg Collaborative. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score. *Br J Surg.* 2021 Nov 11;108(11):1274-1292.
10. COVIDSurg Collaborative. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for tumor types in 61 countries: an international, prospective, cohort study. *Lancet Oncol.* 2021 Nov;22(11):1507-1517.
11. COVIDSurg Collaborative. Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic. *Br J Surg.* 2021 Dec 1;108(12):1448-1464.
12. COVIDSurg Collaborative. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. *Br J Surg.* 2021 Jan 27;108(1):88-96.
13. Pados G, **Zouzoulas D**. Borderline Ovarian Tumors: What Is the Optimal Therapeutic Strategy?. *Handbook of Research on Oncological and Endoscopic Dilemmas in Modern Gynecological Clinical Practice.* IGI Global, 2021; 223-239.
14. Pados G, **Zouzoulas D**, Tsolakidis D. Recent management of endometrial cancer: a narrative review of the literature. *Front. Med.* 10: 1244634.
15. **Zouzoulas D**, Tsolakidis D, Pavlidi O, Pappas P, Theodoridis T, Pados G, Pervana S, Pazarli E, Grimbizis G. Rate of Leiomyosarcomas during Surgery for Uterine Fibroids: 8-Year Experience of a Single Center. *J Clin Med.* 2023 Dec 7;12(24):7555.
16. **Zouzoulas D**, Tsolakidis D, Tzitzis P, et al. The Use of CA-125 KELIM to Identify Which Patients Can Achieve Complete Cytoreduction after Neoadjuvant Chemotherapy in High-Grade Serous Advanced Ovarian Cancer. *Cancers (Basel).* 2024;16(7):1266.
17. **Zouzoulas D**, Tsolakidis D, Tzitzis P, et al. CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study. *Int J Mol Sci.* 2024;25(10):5230.
18. NIHR Global Health Research Unit on Global Surgery; STARSurg Collaborative. A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts. *Lancet Digit Health.* 2024;6(7):e507-e519.

19.	Tsolakidis D, <b>Zouzoulas D</b> , Sofianou I, et al. External Validation of the New 2023 International Federation of Gynecology and Obstetrics Staging System in Endometrial Cancer Patients: 12-Year Experience from an European Society of Gynecological Oncology-Accredited Center. <i>Medicina (Kaunas)</i> . 2024;60(9):1421.
20.	<b>Zouzoulas D</b> , Tsolakidis D, Sofianou I, et al. Molecular classification of endometrial cancer: Impact on adjuvant treatment planning. <i>Cytojournal</i> . 2024;21:47.
21.	<b>Zouzoulas D</b> , Tsolakidis D, Karalis T, Aristotelidis M, Topalidou M, Grimbizis G. The impact of delay from diagnosis to surgery in endometrial cancer. <i>Arch Gynecol Obstet</i> . 2025;311(2):395-404.
22.	<b>Zouzoulas D</b> , Tsolakidis D, Sofianou I, et al. The Impact of Surgery Delay on Early-Stage Ovarian Cancer. <i>Life (Basel)</i> . 2025;15(1):122.
23.	Tsolakidis D, <b>Zouzoulas D</b> , Tzitzis P, et al. The Role of Douglastomy Instead of Random Biopsies in the Surgical Treatment of Presumed FIGO Stage I Ovarian Cancer. <i>Cancers (Basel)</i> . 2025;17(3):419.
24.	Tsolakidis D, Kyziridis D, Panoskaltis T, Kalakonas A, Theodoulidis V, Chatzistamatiou K, <b>Zouzoulas D</b> , Tentes A. Evaluating the Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on Interval and Secondary Debulking in Ovarian Cancer: A Systematic Review. <i>Cancers (Basel)</i> . 2025;17(5):904.
25.	Kartsiounis V, Meditskou S, Siargkas A, Pervana S, Pazarli E, Kalogiannidis I, <b>Zouzoulas D</b> , Tsolakidis D, Papanikolaou A, Dinas K. Expression of NUMB Protein and Its Prognostic Significance in Endometrial Cancer: A Retrospective Cohort Study. <i>Cureus</i> . 2025;17(3):e81402.
26.	Theodoulidis V, Kissoudi K, Chatzistamatiou K, Tzitzis P, <b>Zouzoulas D</b> , et al. Neutrophil-Lymphocyte Ratio and KELIM Score as Prognostic Markers in High-Grade Serous Advanced Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Biomedicines</i> . 2025;13(4):975.
27.	<b>Zouzoulas D</b> , Karalis T, Sofianou I, et al. The Impact of Treatment Delay on Endometrial and Ovarian Cancer Patients: A Systematic Review. <i>Cancers (Basel)</i> . 2025;17(13):2076.
28.	Tsolakidis D, Chatzistamatiou K, Markopoulou E, <b>Zouzoulas D</b> , et al. Utilization of Ligasure® Maryland Jaw Open Sealer/Divider with Nanocoating Improves Perioperative Parameters in Women with Advanced Ovarian Cancer Subjected to Cytoreductive Surgery. <i>J Clin Med</i> . 2025;14(17):6293.
29.	Theodoulidis V, Kissoudi K, Chatzistamatiou K, Tzitzis P, <b>Zouzoulas D</b> , et al. Predictors of Extended Intensive Care Unit Utilization After Ovarian Cancer Surgery. <i>Cancers (Basel)</i> . 2025;17(19):3203.
30.	<b>Zouzoulas D</b> , Chatzistamatiou K, Tsolakidis D. The role of p16/Ki-67 dual staining in cervical cancer screening and cervical precancerous lesions follow-up. <i>Cytojournal</i> . 2025;22:78.
31.	<b>Zouzoulas D</b> , Sofianou I, Tzitzis P, et al. The Role of Delayed Interval Debulking Surgery (DIDS) in the Surgical Treatment of Advanced Epithelial Ovarian Cancer: A Retrospective Cohort from an ESGO-Certified Center. <i>Med Sci (Basel)</i> . 2025;13(4):217.